IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a ...

This week saw two major life sciences investments in London, as GSK unveiled plans to move its headquarters to a central location in the city, while an ambitious plan to develop a new biosciences ...

In the 24th year of the competition, Istanbul will stage its first-ever UEFA Women's Champions League tie this week as ...

It was one of those conversations you never forget. We were discussing – of all things – the Covid injections, and I was questioning the early ‘safe and effective’ claims put forward by the pharmaceut ...

British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

GSK's specialty medicines segment showed strong performance, growing over 20% due to successful new launches. Additionally, GSK is currently undervalued, trading at £16.1, significantly below the ...

Miels said the new plan includes “changing our marketing mix to focus on segments who are tougher to activate.” Making Shields part of the marketing mix has enabled GSK to win mainstream media ...

The company's strategic focus on innovation, particularly in R&D, is evident from its investments in new vaccines and medicines, combining scientific focus on the immune system with advanced ...